| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/03/2003 | US20030124061 Antagonist has significant bioavailability only when said pharmaceutical safety dosage form is disrupted. |
| 07/03/2003 | US20030124050 Controlling temperature, times; agglomeration powders |
| 07/03/2003 | US20030124048 Filler for adhesives, rubbers, cosmetics; precipitating, separation, drying |
| 07/03/2003 | US20030124033 Method and apparatus for liposome production |
| 07/03/2003 | US20030121476 Feeder bottles |
| 07/03/2003 | DE29522419U1 Multiple unit tabletted dosage form contg omeprazole - comprising enteric coated layered units of core material contg omeprazole compressed with excipients into tablets |
| 07/03/2003 | CA2736633A1 Medication delivery system and monitor |
| 07/03/2003 | CA2473935A1 Composition for treating contact lenses |
| 07/03/2003 | CA2471400A1 Vaginal delivery of drugs |
| 07/03/2003 | CA2471396A1 Ultrapure oral fludara formulation with a fast releasing active substance |
| 07/03/2003 | CA2471241A1 Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
| 07/03/2003 | CA2471096A1 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 07/03/2003 | CA2471081A1 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 07/03/2003 | CA2470999A1 Syn3 compositions and methods |
| 07/03/2003 | CA2470912A1 Pharmaceutical suspension for oral administration |
| 07/03/2003 | CA2470859A1 Pharmaceutical composition comprising skim milk powder |
| 07/03/2003 | CA2470857A1 Metered dose inhaler |
| 07/03/2003 | CA2470829A1 Particulate compositions |
| 07/03/2003 | CA2470826A1 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| 07/03/2003 | CA2470776A1 Malleable protein matrix and uses thereof |
| 07/03/2003 | CA2470636A1 Zero-order sustained released dosage forms and method of making the same |
| 07/03/2003 | CA2470603A1 Methods for the treatment of peripheral neural and vascular ailments |
| 07/03/2003 | CA2470443A1 Pharmaceutical compositions based on azetidine derivatives |
| 07/03/2003 | CA2470364A1 Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
| 07/03/2003 | CA2470316A1 Lyophilized preparation containing antibodies to the egf receptor |
| 07/03/2003 | CA2470055A1 Methods for wet granulating azithromycin |
| 07/03/2003 | CA2470003A1 Composition for treating contact lenses in the eye |
| 07/03/2003 | CA2469904A1 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| 07/03/2003 | CA2469246A1 Directly compressible formulations of azithromycin |
| 07/03/2003 | CA2469047A1 Tempamine compositions and methods of use |
| 07/03/2003 | CA2468775A1 Heparin-containing ophthalmic agent |
| 07/03/2003 | CA2468627A1 Liposome composition for delivery of nucleic acid |
| 07/03/2003 | CA2466633A1 Sustained-release compositions |
| 07/02/2003 | EP1323765A1 Biologically absorbable polyhydroxycarboxylic acid and production method thereof |
| 07/02/2003 | EP1323440A1 Peritoneal dialysates |
| 07/02/2003 | EP1323431A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 07/02/2003 | EP1323430A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 07/02/2003 | EP1323426A1 Eye drops |
| 07/02/2003 | EP1323422A1 Pharmaceutical composition comprising midazolam for buccal administration |
| 07/02/2003 | EP1323421A1 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| 07/02/2003 | EP1323418A1 Granular preparations for oral administration |
| 07/02/2003 | EP1323417A1 Tablets quickly disintegrating in the oral cavity and process for producing the same |
| 07/02/2003 | EP1323416A1 Process for producing medicinal solid dispersion |
| 07/02/2003 | EP1323415A1 Method of coating fine particle with lipid film |
| 07/02/2003 | EP1323414A2 Improvements on products intended for human or animal consumption |
| 07/02/2003 | EP1323412A1 Light screening composition comprising a dibenzoylmethane type screening agent and an amino substituted 2-hydroxybenzophenone derivative |
| 07/02/2003 | EP1323404A1 Hard capsule |
| 07/02/2003 | EP1322666A2 Hiv peptides from tat,rev and wef conserved regions and their application as e.gvacine compnents |
| 07/02/2003 | EP1322665A2 Hiv peptidesform concerved regions in gag p17 and 924 and their application in e.g vacines |
| 07/02/2003 | EP1322595A2 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 07/02/2003 | EP1322411A1 Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 07/02/2003 | EP1322378A1 Method and device for avoiding alteration of a substance having biological activities |
| 07/02/2003 | EP1322350A1 E-ptfe foil impregnated with an encapsulated bioactive substance |
| 07/02/2003 | EP1322336A1 Method of increasing testosterone and related steroid concentrations in women |
| 07/02/2003 | EP1322335A2 Stable solid dosage forms of amino acids and processes for producing same |
| 07/02/2003 | EP1322329A1 Split enveloped virus preparation |
| 07/02/2003 | EP1322321A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours |
| 07/02/2003 | EP1322318A1 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 07/02/2003 | EP1322316A1 Diuretic or sulphonylurea for use in antiviral treatment |
| 07/02/2003 | EP1322313A2 Controlled release formulations for oral administration |
| 07/02/2003 | EP1322308A2 Devices and methods for management of inflammation |
| 07/02/2003 | EP1322303A1 Delivery system for multi-pharmaceutical active materials at various release rates |
| 07/02/2003 | EP1322301A1 Combination particles for the treatment of asthma |
| 07/02/2003 | EP1322300A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 07/02/2003 | EP1322299A2 Composition for the transdermal delivery of fentanyl |
| 07/02/2003 | EP1322298A1 Pharmaceutical oxan preparation |
| 07/02/2003 | EP1322297A2 Chrono delivery formulations and method of use thereof |
| 07/02/2003 | EP1322296A1 Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same |
| 07/02/2003 | EP1322295A2 Stabilization of solid drug formulations |
| 07/02/2003 | EP1322294A2 Stabilization of solid thyroid drug formulations |
| 07/02/2003 | EP1322293A1 Modified release formulation |
| 07/02/2003 | EP1322292A2 Microparticle compositions and methods for the manufacture thereof |
| 07/02/2003 | EP1322291A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 07/02/2003 | EP1322290A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 07/02/2003 | EP1322289A1 Spray drying process and compositions of fenofibrate |
| 07/02/2003 | EP1322288A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 07/02/2003 | EP1322287A2 Microparticles for delivery of the heterologous nucleic acids |
| 07/02/2003 | EP1322286A2 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/02/2003 | EP1322275A2 Ultrasonic method and device for wound treatment |
| 07/02/2003 | EP1322182A2 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 07/02/2003 | EP1322169A1 Irreversible coating particles and compositions containing these particles |
| 07/02/2003 | EP1322158A1 Sustained release pharmaceutical compositions containing metformin and method of its production |
| 07/02/2003 | EP1322157A2 Antimicrobial compositions formulated for use in cold temperature conditions and methods of use thereof |
| 07/02/2003 | EP1146856B1 Spheronised self-emulsifying system for hydrophobic and water-sensitive agents |
| 07/02/2003 | EP1124539B1 Pharmaceutical formulation comprising omeprazole |
| 07/02/2003 | EP1041966B1 Pharmaceutical compositions comprising zafirlukast |
| 07/02/2003 | EP1017371B1 Controlled release of drugs delivered by sublingual or buccal administration |
| 07/02/2003 | EP1014954B1 Transdermal therapeutic system |
| 07/02/2003 | EP1006997B1 Effervescent microspheres and method for making them |
| 07/02/2003 | EP0997148B1 Phosphate-binding polymer preparations |
| 07/02/2003 | EP0975327B1 Use of 5ht3 antagonists for promoting intestinal lavage |
| 07/02/2003 | EP0954292B1 Pharmaceutical formulations with delayed drug release |
| 07/02/2003 | EP0894010B1 Denaturants for sympathomimetic amine salts |
| 07/02/2003 | EP0880530B1 Phosphatidyl oligoglycerols |
| 07/02/2003 | EP0801560B1 A controlled release drug suspension delivery device |
| 07/02/2003 | EP0801557B1 Liposome formulations of 5beta steroids |
| 07/02/2003 | EP0781129B1 Pharmaceutical preparation containing metformin and a process for producing it |
| 07/02/2003 | EP0720479B1 Transdermal therapeutic system with acetylsalicylic acid as active substance |
| 07/02/2003 | EP0660714B1 Novel liposomal drug delivery systems |
| 07/02/2003 | EP0626864B1 Topical composition containing hyaluronic acid and nsaids |